Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc. Fundamental Analysis
Odonate Therapeutics, Inc. (ODTC) shows weak financial fundamentals with a PE ratio of 3227.30, profit margin of 0.00%, and ROE of 7.01%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 61.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze ODTC's fundamental strength across five key dimensions:
Efficiency Score
WeakODTC struggles to generate sufficient returns from assets.
Valuation Score
WeakODTC trades at a premium to fair value.
Growth Score
ModerateODTC shows steady but slowing expansion.
Financial Health Score
ExcellentODTC maintains a strong and stable balance sheet.
Profitability Score
WeakODTC struggles to sustain strong margins.
Key Financial Metrics
Is ODTC Expensive or Cheap?
P/E Ratio
ODTC trades at 3227.30 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ODTC's PEG of 32.27 indicates potential overvaluation.
Price to Book
The market values Odonate Therapeutics, Inc. at 218.64 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 854.03 times EBITDA. This signals the market has high growth expectations.
How Well Does ODTC Make Money?
Net Profit Margin
For every $100 in sales, Odonate Therapeutics, Inc. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.01 in profit for every $100 of shareholder equity.
ROA
Odonate Therapeutics, Inc. generates $6.63 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $8.14 in free cash annually.
FCF Yield
ODTC converts 0.11% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
3227.30
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
32.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
218.64
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
111.72
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How ODTC Stacks Against Its Sector Peers
| Metric | ODTC Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 3227.30 | 29.45 | Worse (Expensive) |
| ROE | 7.01% | 779.00% | Weak |
| Net Margin | 0.00% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.02 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 111.72 | 4.65 | Strong Liquidity |
| ROA | 6.63% | -19344.00% (disorted) | Weak |
ODTC outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Odonate Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation